Findings

What do systematic reviews say?

13 questions · 13 findings · 5 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 38.5%GRADE not reported 1 · 7.7%Very low 0 · 0%Low 2 · 15.4%Moderate 5 · 38.5%High 0 · 0%

Anticoagulant vs different dose of the same anticoagulant

All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 278 participants
Moderate

Anticoagulant vs placebo or no treatment

All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.36 [0.04, 3.61]
5 studies · 1777 participants
Low

Anticoagulant vs antiplatelet agent

All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 279 participants
Moderate

Anticoagulant vs placebo or no intervention

Overall mortality ( · people with distal DVT

Anticoagulant showed no clear difference in overall mortality ( compared with no intervention or placebo (low certainty).

1 finding from 1 review

Treatment of distal deep vein thrombosis 2020 · Cochrane Headline outcomes only
RR 3.2 [0.13, 77.69]
3 studies · 430 participants
Low

Anticoagulant vs placebo or no intervention

Mortality related to PE ( · people with distal DVT

1 finding from 1 review

Treatment of distal deep vein thrombosis 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 430 participants
GRADE not reported

Anticoagulant with or without ASA vs ASA only

All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aspirin vs placebo

All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ASA with LMWH vs placebo or IVIG

All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH

All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral factor Xa inhibitors vs conventional anticoagulation

All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral factor Xa inhibitors showed no clear difference in all‐cause mortality compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 1.16 [0.79, 1.7]
1 study · 4817 participants
Moderate

Oral direct thrombin inhibitors (DTIs) vs conventional anticoagulation

All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques

The review found no eligible studies for this question.

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral direct thrombin inhibitors (DTIs) vs conventional anticoagulation

All‐cause mortality (7 months) · participants with diagnosed DVT

Oral DTIs showed no clear difference in all‐cause mortality (7 months) compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.66 [0.41, 1.08]
1 study · 2489 participants
Moderate

Oral factor Xa inhibitors vs conventional anticoagulation

All‐cause mortality (3 to 6 months) · participants with diagnosed DVT

Oral factor Xa inhibitors showed no clear difference in all‐cause mortality (3 to 6 months) compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.87 [0.67, 1.14]
9 studies · 10770 participants
Moderate